Preview

Medical Herald of the South of Russia

Advanced search

Adaptive immune response in patients with atherosclerosis before and after coronary bypass surgery

https://doi.org/10.21886/2219-8075-2023-14-1-125-134

Contents

Scroll to:

Abstract

Objective: to assess changes in the immune status before and after coronary bypass surgery.
Materials and methods: included 70 male patients with coronary atherosclerosis (group 1) and 30 volunteers (group 2) without signs of coronary artery disease comparable in age to group 1. Immunity parameters were studied before surgery, after 4–5, 9–10 and 28–30 days by the method of phenotyping of CD3+ populations; CD3+CD4+; CD3+CD8+; CD3+CD25+; CD3+CD45+; CD3+CD95+; CD4+CD25+; CD4+CD154+; CD19+, CD19+CD40+. The levels of Ig A, M, G were assessed by the method of radial immunodiffusion in the gel. Serum precipitation in polyethylene glycol was used to determine circulating immune complexes. Statistical analysis of the study results was performed using the Statistica 12.0 program (StatSoft, USA). Statistical significance was considered significant at p<0.05.
Results: in patients of the IHD group, uncoupling of the processes of T-lymphocyte activation, their maturation and apoptosis was noted; suppression of immunoregulation and activation of intercellular cooperation. After CABG, in dynamics, these processes reflect the multidirectional changes.
Conclusions: in patients with coronary atherosclerosis, there is a discoordination of the processes of T-lymphocyte activation, their maturation and apoptosis. Suppression of immunoregulation and activation of intercellular cooperation. In the dynamics after CABG, immunity parameters differ in different directions in different periods of observation and demonstrate different degrees of involvement of adaptive mechanisms of immune defense.

For citations:


Shlyk I.F., Sizyakina L.P., Evsegneeva I.V., Shlyk S.V., Besedina D.Yu., Makarchuk I.V. Adaptive immune response in patients with atherosclerosis before and after coronary bypass surgery. Medical Herald of the South of Russia. 2023;14(1):125-134. (In Russ.) https://doi.org/10.21886/2219-8075-2023-14-1-125-134

Introduction

Today, atherosclerosis is one of the biggest challenges. Based on the Framingham Heart Study, the authors estimate that annual mortality due to clinical manifestations of atherosclerosis will reach 22 million by 2030 [1]. What is striking about this problem is that despite decades of research, the pathological mechanisms of atherosclerosis have not been clearly understood yet. Multifocal atherosclerotic disease affecting different arterial systems is associated with a wide variety of clinical symptoms. Coronary atherosclerosis accounting for about 60% of cases has been reported as a risk factor for ischemic heart disease (IHD) [2]. Atherosclerosis is an inflammatory disease, in which immunocompetent cells migrate into the vascular sub-endothelium, contributing to the build-up of atherosclerotic plaque. As with any inflammatory response, atherosclerosis is associated with activation of innate immunity (the first line of defense) and acquired immunity mediated by antigen-specific mechanisms [3].

Many literature publications focus on the involvement of adaptive immune response in patients with atherosclerosis; however, there are only a few studies that have described changes in the immune status after coronary artery bypass surgery.

The aim of the study was to evaluate changes in the immune status before and after coronary artery bypass surgery.

Materials and Methods

It was an open-label, cross-sectional study. It was conducted at the Rostov State Medical University of the Russian Ministry of Health between 2017 and 2019. Cardiac surgical patients with coronary atherosclerosis were enrolled. The Clinical Immunology and Allergology Research Institute of the Rostov State Medical University was responsible for clinical pathology. This study followed the principles of the WMA Declaration of Helsinki and was approved by the local ethics committee. The study included 70 patients with coronary atherosclerosis (group I) undergoing pre-operative direct coronary angiography and coronary artery bypass surgery supported by the clinical guidelines for the management of patients with stable IHD. The patients underwent a beating heart bypass. To compare the adaptive immune responses, 30 volunteers (group II) with no clinical and instrumental signs of IHD were studied. Both groups consisted of age-matched male patients (57.02±1.7 and 54.9±1.3 years, respectively, P = 0.33). IHD patients with evidence of an ongoing or prior infection were excluded from the study. Diabetes mellitus, rheumatic diseases, connective tissue disorders, benign and malignant neoplasms, and bad health habits were among the exclusion criteria. The immune status was assessed prior to surgery, on postoperative days 4–5, 9–10, and 28–30, i.e. in the early postoperative period. The lymphocyte phenotyping panels (CD3+, CD3+CD4+, CD3+CD8+, CD3+CD25+, CD3+CD45+, CD3+CD95+, CD4+CD25+, CD4+CD154+ subpopulations) were obtained by laser flow cytometry. Foxp3 and Granzyme B+ expression profiles were assessed in the peripheral mononuclear cells isolated by standard Ficoll-Verografin gradient centrifugation. For labeling, mononuclear cells were permeabilized with the IntraPrep Permeabilization Reagent (Immunotech) and stained with anti-Foxp3 (eBioscience) and anti-Granzyme B (Serotec) monoclonal antibodies. Samples were analyzed using the Cytomics FC 500 Flow Cytometer (Beckman Coulter).

B-lymphocytes (CD19+, CD19+CD40+) were identified by flow cytometric analysis (Beckman Coulter Cytomics FC 500) using specific monoclonal antibodies. IgA, IgG, and IgM were quantified by radial gel immunodiffusion using anti-heavy chain monospecific antibodies (Microgen, Russia). The values were expressed as g/L.

Serum circulating immune complexes (CICs) were detected by polyethylene glycol precipitation. Spectrophotometry was used for the quantitative evaluation of CICs at 450 nm, with the recorded values expressed in standard units. The data collected were statistically analyzed using the Statistica 12.0 package (StatSoft, USA). The descriptive statistics were summarized including mean (M) and its standard error (m). The mean difference between the groups was estimated by the Mann-Whitney test, and the Wilcoxon rank sum test was used to compare surgical outcomes over time. The distribution of study variables was analyzed using the Shapiro-Wilk test assessing whether the variables were normally distributed. The P-value <0.05 was considered statistically significant.

Results

The analysis of T-lymphocyte counts revealed a statistically significant increase in the relative numbers of the CD3+ subpopulation in the IHD group compared to the control group. The expression of early activation markers (CD3+CD25+) was increased in the IHD patients, whereas HLA DR expression on T-lymphocytes was found to be decreased. Moreover, the patients from the IHD group had significantly decreased apoptosis marker expression levels and annexin-positive cells. A significant increase in circulating CD45R0+ memory T-lymphocytes was shown in the IHD group vs. the control group. IHD was also associated with a decline in a naïve T lymphocyte (CD45RA+) pool (Table 1).

Table 1

Quantitative and functional parameters of T-lymphocytes in patients with coronary heart disease (CHD)

Indicator

CHD, (n=70)

Control group, (n=30)

P

CD3+, %

72.7±0.8

66.2±0.77

0.0002

CD3+, 109/l

1.5±0.09

1.14±0.05

0.07

CD3+CD25+, %

3.1±0.68

1.8±0.15

0.02

CD3+CD25+, 109/l

0.06±0.01

0.03±0.001

0.002

CD3+HLA DR+, %

3.7±0.8

7.8±0.14

0.00005

CD3+HLA DR+, 109/l

0.07±0.01

0.13±0.001

0.0001

CD3+CD95+, %

1.7±0.6

5.1±0.08

0.00005

CD3+CD95+, 109/l

0.03±0.01

0.07±0.001

0.02

CD3+An+, %

2.3±0.4

6.1± 0.11

0.0004

CD3+An+, 109/l

0.04±0.01

0.1±0.01

0.0005

CD3+CD45RO+, %

34.4±2.1

21.4± 0.4

0.00006

CD3+CD45RO+, 109/l

0.61±0.04

0.57±0.06

0.17

CD3+ CD45RA+, %

23.0±1.8

30.2±0.43

0.04

CD3+ CD45RA+, 109/l

0.40±0.07

0.33±0.04

0.36

Note: the significance level was taken at p<0.05. The p-value was obtained by comparing groups among themselves. The data are presented as M±m.

Analysis of the T-lymphocyte subpopulation was equivocal, with a relative increase in CD4+-lymphocytes in the IHD patients. No differences in CD3+CD8+ lymphocyte counts between the groups were reported, and no intergroup changes in immunoreactive insulin (IRI) levels may be considered predictable. The IHD group was remarkable for reliably higher concentrations of intracellular Granzyme B and CD4+ T-lymphocytes expressing early activation marker (CD25+), as well as for an increase in CD4+ cells known to express CD154+ (CD40L) on their surfaces, which is essential in activating B-lymphocytes. However, immunoregulatory CD4+CD25+Foxp3+ T cells significantly decreased (Table 2).

Table 2

Characteristics of T-lymphocyte subpopulations in patients in the CHD group

Indicator

CHD, (n=30)

Control group, (n=30)

P

CD3+CD4+, %

45.1±1.0

40.82±0.33

0.008

CD3+CD4+, 109/l

0.83±0.05

0.76±0.04

0.56

CD3+CD8+, %

27.15±0.9

25.0±0.94

0.56

CD3+CD8+, 109/l

0.53±0.03

0.48±0.01

0.06

CD8+Gr+, %

18.7±1.0

8.2±0.68

0.00002

CD8+Gr+, 109/l

0.33±0.03

0.08±0.02

0.00002

IRI

1.87±0.1

1.69±0.07

0.88

CD4+CD25+, %

2.5±0.1

1.83±0.1

0.02

CD4+CD25+, 109/l

0.04±0.007

0.025±0.001

0.04

CD4+CD25+Foxp3+, %

1.85±0.3

3.11±0.4

0.008

CD4+CD25+Foxp3+, 109/l

0.03±0.007

0.10±0.001

0.009

CD4+CD154+, %

0.9±0.02

0.41±0.01

0.0002

CD4+CD154+, 109/l

0.006±0.003

0.002± 0.001

0.03

Note: the significance level was taken at p<0.05. The p-value was obtained by comparing groups among themselves. The data are presented as M±m.

In the IHD group, the adaptive humoral immune response was associated with an increase in CD19+ cells, circulating B-lymphocytes with CD40-receptor mediating cell-to-cell communication, and higher production of the primary classes of immunoglobulins (IgA, IgM, IgG) (Table 3).

Table 3

Indicators of the humoral link of adaptive immunity in patients with coronary heart disease

Indicator

CHD, (n=30)

Control group, (n=30)

P

CD19+, %

13.15±0.4

8.35±0.47

0.002

CD19+, 109/l

0.18±0.01

0.17±0.02

0.9

CD19+CD40+, %

8.8±0.7

6.58±0.11

0.02

CD19+CD40+, 109/l

0.2±0.01

0.09±0.01

0.03

IgA g/l

2.2±0.05

1.6±0.08

0.0001

IgM g/l

1.4±0.03

1.19±0.02

0.04

IgG g/l

11.75±0.12

10.72±0.26

0.0006

CIC, c.u.

70.76±2.5

59.18±2.22

0.04

Note: the significance level was taken at p<0.05. The p-value was obtained by comparing groups among themselves. The data are presented as M±m.

A comparison of the immune responses in both groups demonstrated the following differences. The dissociation of T-lymphocyte activation, maturation and apoptosis, suppression of immunoregulation and upregulation of cell cooperation could be observed in the IHD patients.

Coronary artery bypass grafting (CABG) remains the gold standard procedure for IHD, however, as any surgical intervention, it affects all body systems for regulating homeostasis, including the immune system. Due to the fundamental contribution the immune system makes to all stages of atherogenesis, it is considered appropriate to scrutinize the CABG-related mechanisms of immune response in IHD patients and compare between the groups based on recurrent adverse events.

Changes in Humoral and Cell-Mediated Immune Responses

Analysis of T-lymphocyte values within 1 month of CABG demonstrated slight variations in CD3+-lymphocytes, as well as in cells expressing early (CD3+CD25+) and late (CD3+HLA DR+) activation markers. However, these variations were not statistically significant. It is noteworthy to characterize the lymphocytes expressing the apoptosis marker CD95: relative and absolute counts of CD3+CD95+ cells significantly decreased by postoperative days 4, 5, and 12, and returned to baseline one month after the intervention. Similar changes were observed in annexin-stained cells. No significant trends were reported for CD45RO+ T-cells, while CD45RA+ naïve T-lymphocyte counts statistically significantly decreased within the same period and 12 days following the CABG, and returned to baseline one month after the intervention (Table 4).

Table 4

Dynamics of quantitative and functional parameters of T-lymphocytes in patients after CABG

Indicator

Before surgery

4th–5th days

9th–10th days

1 month

P

CD3+, %

72.7±0.8

70.7±1.2

71.5±1.6

69.7±1.5

1–0.3

2–0.8

3–0.1

CD3+, 109/l

1.5±0.09

1.2±0.1

1.7±0.1

1.3±0.1

1–0.1

2–0.3

3–0.2

CD3+CD25+, %

3.1±0.68

5.7±1.4

3.1±0.5

5.3±1.9

1–0.3

2–0.8

3–0.4

CD3+CD25+, 109/l

0.06±0.01

0.06±0.01

0.05±0.01

0.05±0.001

1–0.3

2–0.1

3–0.5

CD3+HLA DR+, %

3.7±0.8

3.6±0.8

5.2±1.5

4.9±1.2

1–0.9

2–0.4

3–0.3

CD3+HLA DR+, 109/l

0.07±0.01

0.06±0.01

0.08±0.01

0.07±0.01

1–0.2

2–0.5

3–0.1

CD3+CD95+, %

1.7±0.6

0.4±0.05

0.2±0.01

2.5±0.09

1–0.01

2–0.01

3–0.4

CD3+CD95+, 109/l

0.03±0.01

0.003±0.001

0.001±0.0001

0.03±0.01

1–0.01

2–0.02

3–0.7

CD3+An+, %

2.3±0.4

1.1±0.04

0.8± 0.1

3.6±0.2

1–0.009

2–0.01

3–0.06

CD3+An+, 109/l

0.04±0.01

0.04±0.01

0.01±0.001

0.05±0.01

1–0.4

2–0.2

3–0.2

CD3+CD45RO+, %

34.4±2.1

36.2±1.5

30.8±1.2

28.5± 1.3

1–0.06

2–0.9

3–0.4

CD3+CD45R0+, 109/l

0.61±0.04

0.65±0.04

0.71±0.07

0.5±0.06

1–0.17

2–0.6

3–0.08

CD3+ CD45RA+, %

23.0±1.8

17.1±1.5

16.2±1.6

22.2±1.7

1–0.04

2–0.05

3–0.7

CD3+ CD45RA+, 109/l

0.40±0.07

0.23±0.07

0.18±0.04

0.33±0.04

1–0.03

2–0.02

3–0.2

Note: the significance level was taken at p<0.05. 1 — comparison between indicators before surgery and after 4–5 days after surgery; 2 — comparison between values before surgery and 10–12 days after surgery; 3 — comparison between values before surgery and 1 month after surgery. The data are presented as M±m.

T-cell subpopulation profiles contained no significant changes in CD3+CD4+-lymphocytes within a month post CABG. However, CD3+CD8+ cytotoxic lymphocytes showed a statistically significant decrease by postoperative days 4–5 and 10–12. These changes resulted in a significant increase in IRI levels on days 4, 5, and 12 of the intervention. Those time points were also remarkable for a decrease in the functional activity of CD8+-lymphocytes equivalent to Granzyme B (CD8+Gr+) concentrations. CD3+CD4+-cells expressing early activation marker (CD25+), CD4+CD25+Foxp3+ lymphocytes, CD154+ (CD40L) expressing cells remained unchanged within one month of follow-up (Table 5).

Table 5

Characterization of T-lymphocyte subpopulations in patients after CABG

Indicator

Before surgery

4th-5th days

9th-10th days

1 month

P

CD3+CD4+, %

45.1±1.0

48.7±1.58

52.0±1.92

46.3±1.67

1–0.4

2–0.06

3–0.7

CD3+CD4+, 109/l

0.83±0.05

0.83±0.07

1.21±0.14

0.84±0.08

1–0.1

2–0.08

3–0.2

CD3+CD8+, %

27.15±0.9

21.7±1.18

19.4±1.15

23.6±1.34

1–0.04

2–0.001

3–0.3

CD3+CD8+, 109/l

0.53±0.03

0.38±0.04

0.40±0.04

0.40±0.03

1–0.05

2–0.1

3–0.1

CD8+Gr+, %

18.7±1.0

15.3±1.43

15.9±1.05

16.9±1.4

1–0.3

2–0.4

3–0.8

CD8+Gr+, 109/l

0.33±0.03

0.24±0.04

0.3±0.04

0.3±0.04

1–0.2

2–0.8

3–0.9

IRI

1.87±0.1

2.44±0.1

2.91±0.26

2.03±0.15

1–0.05

2–0.001

3–0.8

CD4+CD25+, %

2.5±0.1

3.9±0.1

2.3±0.6

3.84±0.1

1–0.4

2–0.6

3–0.5

CD4+CD25+, 109/l

0.04±0.007

0.06±0.003

0.04±0.006

0.06±0.001

1–0.2

2–0.7

3–0.2

CD4+CD25+Foxp3+, %

1.85±0.3

2.9±0.7

2.0±0.5

2.6±0.8

1–0.5

2–0.6

3–0.8

CD4+CD25+Foxp3+, 109/l

0.03±0.007

0.04±0.005

0.03±0.005

0.05±0.001

1–0.5

2–0.6

3–0.8

CD4+CD154+, %

0.9±0.02

0.8±0.04

0.7±0.06

0.8±0.02

1–0.06

2–0.1

3–0.9

CD4+CD154+, 109/l

0.006±0.003

0.01±0.001

0.009±0.001

0.008± 0.001

1–0.06

2–0.2

3–0.3

Note: the significance level was taken at p<0.05. 1 — comparison between indicators before surgery and 4–5 days after surgery; 2 — comparison between values before surgery and 10–12 days after surgery; 3 — comparison between values before surgery and 1 month after surgery. The data are presented as M±m.

Starting from day 12 up to one month of the intervention, the adaptive humoral immune response was characterized by an increase in B-cells. From days 4–5 onwards, B-lymphocytes expressing CD40 receptor mediating cell-to-cell communication increased and remained significantly elevated after 1 month of the follow-up. It should be noted that the functional activity of B-cells producing immunoglobulins A, M, and G did not change significantly within one-month follow-up. Significant trends could be demonstrated in CIC profiles, with their levels increasing on days 4–5 postoperatively and gradually decreasing by the end of the follow-up period (Table 6).

Table 6

Dynamics of indicators of the humoral link of adaptive immunity in patients after CABG

Indicator

Before surgery

4th5th days

9th10th days

1 month

P

CD19+, 109/l

0.18±0.01

0.22±0.02

0.31±0.04

0.34±0.03

1–0.9

2–0.07

3–0.06

CD19+CD40+, %

8.8±0.7

13.4±0.4

12.8±0.7

11.7±0.1

1–0.01

2–0.02

3–0.01

CD19+CD40+, 109/l

0.2±0.01

0.18±0.01

0.17±0.02

0.16±0.01

1–0.03

2–0.02

3–0.79

IgA g/l

2.2±0.05

2.17±0.08

2.29±0.09

2.36±0.10

1–0.5

2–0.6

3–0.3

IgM g/l

1.4±0.03

1.35±0.08

1.30±0.06

1.33±0.07

1–0.4

2–0.7

3–0.5

IgG g/l

11.75±0.12

11.8±0.2

11.7±0.20

11.4±0.26

1–0.4

2–0.7

3–0.5

CIC, c.u.

70.76±2.5

107.0±10.8

91.2±8.2

79.9±7.41

1–0.01

2–0.1

3–0.06

Note: the significance level was taken at p<0.05. 1 — comparison between indicators before surgery and 4–5 days after surgery; 2 — comparison between values before surgery and 10–12 days after surgery; 3 — comparison between values before surgery and 1 month after surgery. The data are presented as M±m.

Thus, the results of follow-up immune response monitoring in the patients subjected to CABG are characterized by varying patterns at different time points and demonstrate the differentiated involvement of adaptive defense mechanisms.

Discussion

In this study, the IHD patients were characterized by a decrease in peripheral naïve T-lymphocytes bound to antigen-presenting cells to differentiate into different T-helper subpopulations. It should be emphasized that in addition to a decrease of circulating naïve T-cells, the IHD patients had a higher proportion of CD4+CD45R0+ memory T-lymphocytes subpopulation compared to the control group. The obtained results are consistent with the authors who demonstrated the correlation between memory T-lymphocyte counts and the severity of coronary atherosclerosis, with the highest CD4+CD45R0+ levels in patients with acute IHD [4][5].

Characterization of T-cell activation performance was inconclusive and related to immunogenic dysregulation. There was an increase in T-lymphocytes expressing early activation marker CD25+ and a decrease in T-lymphocytes expressing late activation marker HLA DR+. The results presented in this paper are in line with the findings published by Golderova et al. (2011), who reported an increase in CD25-expressing T-lymphocytes in patients with multifocal coronary artery disease with no relevant changes in single-vessel coronary lesions [6].

An elevated expression of this marker indicates the potential for the T helper-mediated activation of effector mechanisms. This was confirmed by the evidence of the increased IL-2 (CD25) receptor expression on CD4+ T-cells. The obtained data are compatible with the results of the authors who have shown the increase in this marker specific for more severe forms of IHD (acute coronary syndrome and unstable angina pectoris) and its association with increased serum IL-6 and IFN-γ [7][8]. A decrease in T-lymphocytes expressing late activation marker HLA DR may be due to the fact that different stages of atherosclerosis are characterized by morphologies showing CD3+HLADR+lymphocytes in atheroma but not in peripheral blood flow [9]. There are publications reporting a decrease in HLA DR expression on peripheral lymphocytes in stable IHD and an increase related to myocardial infarction and unstable angina [8][10].

Although CD4+ T-lymphocytes expressing early activation marker CD 25+ increased, a decrease in CD4+CD25+Foxp3+ cells performing as an immunoregulatory subpopulation was observed. A decrease in the peripheral counts of these cells is one of the contributors to the development of autoimmune aggression [11]. It is associated with more severe coronary atherosclerosis [12]. Regulatory T cells (Treg cells) display a suppressor function by synthesizing anti-inflammatory cytokines IL-10, IL-35, and THFR-1β [5]. Moreover, oxidized low-density lipoproteins (LDLs) have been found to inhibit the expression of the Foxp3 regulator in CD4+CD25+-lymphocytes, resulting in that they lose their immunoregulatory function [13]. Moreover, the patients with atherosclerosis had lower immunosuppressive activity of CD4+CD25+Foxp3+ along with elevated serum TNF-α [14]. It should be highlighted that a similar pattern has been reported in this paper and is consistent with the authors who established a decrease in CD4+CD25+Foxp3+ cells in patients with acute coronary syndrome without ST-segment elevation [15] and angina pectoris [16]. T-lymphocyte responses to upregulation stimuli facilitate further IHD-specific immunopathogenesis pathways associated with proliferation or apoptosis. In atherosclerotic IHD, dissociation of these processes was disclosed as contrasted with the control group. A CD3+ subpopulation expressing an apoptosis marker (CD95+) and annexin-stained CD3+ cells, i.e. those involved in the programmed cell death process, decreased significantly [6]. This was also suggested by Pasqui et al. (2003), who showed this correlation in patients with myocardial infarction vs. patients with stable angina [8]. The apoptosis/proliferation imbalance with a gain of apoptosis inhibition and higher proliferative activity of T-lymphocytes maintains progressive inflammation in atherosclerosis and may be indicative of autoimmune response, including to endogenous antigens [17][18].

In this study, elevated CD154 expression on CD4+ lymphocytes, as well as CD40 expression on B-lymphocytes, reflects the activation of T-B interaction, with the latter to be upregulated. A coreceptor molecule on T-lymphocytes and a receptor on B-lymphocytes transform the B-cell population into plasma cells actively producing different classes of immunoglobulins, mostly IgG, whereas the absence of such interaction largely results in IgM production. In addition, this interaction contributes to the upregulation of cytotoxic T-lymphocytes and increases their effector potential [19]. This suggestion is consistent with the results of this study, which demonstrates an increase in both absolute counts of CD8+ lymphocytes and their cytolytic activity mediated by intracellular Granzyme B levels [20].

Analysis of CD3+ lymphocyte profiles showed that the IHD group experienced greater apoptosis inhibition post CABG, as well as a decrease in annexin-positive cells and naïve T-lymphocytes, which may be related to the use of glucocorticosteroids in the early postoperative period and surgical stress. The early postoperative period was remarkable for slight cyclic changes in Treg cells, which probably reflects a decrease in the proinflammatory immune response as evidenced by a decrease in cytotoxic T-lymphocyte counts and an increase in IRI levels. CD4+CD25+Foxp3+ lymphocytes are known to control the processes of proliferation/apoptosis, and a decrease in Treg cells is associated with their imbalance [11]. This suggestion could be demonstrated by a decrease of both CD3+CD95+ cells and T-lymphocytes involved in the programmed cell death vs. reference values.

There were insignificant changes in CD154 T-lymphocytes in the early postoperative period compared to baseline elevations. An increase in B-lymphocytes and CD40 B-cells was also reported. These changes were probably due to the persistent autoimmune response to oxidized LDLs.

Conclusion

Thus, the dissociation of T-lymphocyte activation, maturation and apoptosis, suppression of immunoregulation, and upregulation of cell cooperation could be observed in coronary artery disease. The results of follow-up immune response monitoring in the patients subjected to CABG are characterized by varying patterns at different time points and demonstrate the differentiated involvement of adaptive defense mechanisms.

References

1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999-1008. https://doi.org/10.1016/S0140-6736(13)61752-3

2. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2950-9. Erratum in: Eur Heart J. 2015;36(13):794. PMID: 25139896. https://doi.org/10.1093/eurheartj/ehu299

3. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol. 2010;134(1):33-46. https://doi.org/10.1016/j.clim.2009.07.002

4. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, et al. Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. J Am Heart Assoc. 2012;1(1):27-41. https://doi.org/10.1161/JAHA.111.000125

5. Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol. 2011;8(6):348-58. https://doi.org/10.1038/nrcardio.2011.62

6. Golderova A.S., Nikolaeva I.N., Romanovа A.N., Kozlov V.A. The phenotypic characteristic of peripheral blood lymphocytes at the coronary and multifocal atherosclerosis. The Bulletin of Siberian Branch of Russian Academy of Medical Sciences. 2011;31(3):27-31. (In Russ.). eLibrary ID:17752578

7. Zaporozhets T.S., Maistrovskiy К.V., Rapovka V.G., Gazha A.K., Smolina Т.Р., Zvyagintseva T.N. Role of T-cell dysfunction in the development of lower limb atherosclerosis and treatment opportunities. Pacific medical journal. 2009;(3):110-115. (In Russ.) eLIBRARY ID: 13008313

8. Pasqui AL, Di Renzo M, Bova G, Bruni F, Puccetti L, Pompella G, Auteri A. T cell activation and enhanced apoptosis in non-ST elevation myocardial infarction. Clin Exp Med. 2003;3(1):37-44. https://doi.org/10.1007/s102380300014

9. Pigarevsky P.V. Morphometric investigation of immunoregulatory and effector cells in aorta and paraaortic lymph nodes in human atherogenesis. Cytokines and inflammation. 2002;1(4):21-26. (In Russ.). eLibrary ID:9124341

10. Czyz A, Kołacz E, Angerer D, Zawilska K. Expression of activation antigens on lymphocyte surface and circulating platelet-leukocyte aggregates in ischaemic heart disease. Kardiol Pol. 2005;62(3):189-200; discussion 201. PMID: 15830013.

11. Kozlov V.A. Immune paradigm and immunosuppressive dominance in the pathogenesis of major diseases of the modern man. Bulletin of Siberian Medicine. 2019;18(1):7-17. (In Russ.) https://doi.org/10.20538/1682-0363-2019-1-7-17

12. Maganto-García E, Tarrio ML, Grabie N, Bu DX, Lichtman AH. Dynamic changes in regulatory T cells are linked to levels of diet-induced hypercholesterolemia. Circulation. 2011;124(2):185-95. https://doi.org/10.1161/CIRCULATIONAHA.110.006411

13. Mor A, Philips MR, Pillinger MH. The role of Ras signaling in lupus T lymphocytes: biology and pathogenesis. Clin Immunol. 2007;125(3):215-23. https://doi.org/10.1016/j.clim.2007.08.008

14. Wang J, van Dongen H, Scherer HU, Huizinga TW, Toes RE. Suppressor activity among CD4+,CD25++ T cells is discriminated by membrane-bound tumor necrosis factor alpha. Arthritis Rheum. 2008;58(6):1609-18. https://doi.org/10.1002/art.23460

15. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, et al. Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(9):1832-41. https://doi.org/10.1161/ATVBAHA.110.206813

16. Ji QW, Guo M, Zheng JS, Mao XB, Peng YD, et al. Downregulation of T helper cell type 3 in patients with acute coronary syndrome. Arch Med Res. 2009;40(4):285-93. https://doi.org/10.1016/j.arcmed.2009.04.002

17. Sepiashvili R.I., Shubich M.G., Kolesnikova N.V., Slavjanskaja T.A., Lomtatidze L.V. Apoptosis in immunological processes. Allergologija i immunologija. 2015;16(1):101-107. (In Russ.). eLibrary ID:23561301

18. Virtue A, Mai J, Wang H, Yang X. Lymphocytes and Atherosclerosis. Atherosclerosis: Cellular, Molecular & Biochemical Mechanism and Novel Therapy. John Wiley & Sons, Inc.; 2015.

19. Rouwet E, Lutgens E. 2016 Jeffrey M. Hoeg Award Lecture. Arterioscler Thromb Vasc Biol. 2018;38(8):1678-1688. https://doi.org/10.1161/ATVBAHA.118.307742

20. Shevchenko O.P., Prirodova O.F., Shevchenko A.O. Clinical significance of soluble CD40 ligand in patients with ischemic heart disease. Kardiovaskuljarnaja terapija i profilaktika. 2006;5(7):101-111. (In Russ.). eLibrary ID:9954744


About the Authors

I. F. Shlyk
Rostov State Medical University
Russian Federation

Irina F. Shlyk, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Clinical Immunology and Allergology 

Rostov-on-Don


Competing Interests:

The authors declare no conflict of interest.



L. P. Sizyakina
Rostov State Medical University
Russian Federation

Lyudmila P. Sizyakina, Dr. Sci. (Med.), Professor, Head of the Department of Clinical Immunology and Allergology 

Rostov-on-Don


Competing Interests:

The authors declare no conflict of interest.



I. V. Evsegneeva
First Moscow State Medical University named after I.M. Sechenov (Sechenov University)
Russian Federation

Irina V. Evsegneeva, Dr. Sci. (Med.), Professor, Professor of the Department of Clinical Immunology and Allergology 

Moscow


Competing Interests:

The authors declare no conflict of interest.



S. V. Shlyk
Rostov State Medical University
Russian Federation

Sergey V. Shlyk, Dr. Sci. (Med.), Professor, Head of the Department of Therapy 

Rostov-on-Don


Competing Interests:

The authors declare no conflict of interest.



D. Yu. Besedina
Rostov State Medical University
Russian Federation

Daria Yu. Besedina, Resident of the Department of Therapy 

Rostov-on-Don


Competing Interests:

The authors declare no conflict of interest.



I. V. Makarchuk
Rostov State Medical University
Russian Federation

Irina V. Makarchuk, 6th year student, Faculty of Preventive Medicine 

Rostov-on-Don


Competing Interests:

The authors declare no conflict of interest.



Review

For citations:


Shlyk I.F., Sizyakina L.P., Evsegneeva I.V., Shlyk S.V., Besedina D.Yu., Makarchuk I.V. Adaptive immune response in patients with atherosclerosis before and after coronary bypass surgery. Medical Herald of the South of Russia. 2023;14(1):125-134. (In Russ.) https://doi.org/10.21886/2219-8075-2023-14-1-125-134

Views: 462


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2219-8075 (Print)
ISSN 2618-7876 (Online)